← Back to Search

Sulforaphane for Age-Related Issues

N/A
Recruiting
Research Sponsored by Northern Arizona University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and women, 60 years and older
Maximal oxygen consumption below the 60th percentile based on gender: Women: ≤ 21.2 mL/kg/min Men: ≤ 30.5 mL/kg/min
Must not have
History of a myocardial infarction within the last 6 months, clinically significant aortic stenosis, use of cardiac defibrillator, or uncontrolled angina
Any chronic illness that could affect outcome measures, including diabetes, liver or renal disease, or cancer (other than skin cancer)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up comparing trials separated by one week (supplement vs. placebo)

Summary

This trial is testing if adding a natural compound from vegetables to exercise can make exercise more effective for older adults. The study focuses on people aged 60 and above, who typically don't respond as well to exercise. The treatment aims to boost a protective protein in the body, helping cells stay healthy and improving overall well-being.

Who is the study for?
This trial is for men and women aged 60 or older who can consent to participate, have passed a screening, and have lower than average maximal oxygen consumption. People with recent heart attacks, severe heart conditions, current smokers, those on certain medications like statins or blood pressure drugs, and individuals with chronic illnesses such as diabetes cannot join.
What is being tested?
The study is testing if sulforaphane—a compound in cruciferous vegetables—can boost the benefits of exercise in older adults. Participants will either receive sulforaphane capsules or placebo capsules without knowing which one they are taking.
What are the potential side effects?
Sulforaphane may cause gas or bowel irritation due to its effects on digestion. Since it's derived from vegetables like broccoli, people sensitive to these might experience similar discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 60 years old or older.
Select...
My oxygen consumption is below the recommended level for my gender.
Select...
I am capable of understanding and agreeing to the trial's terms on my own.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a heart attack in the last 6 months, have severe heart valve narrowing, use a heart shock device, or have uncontrolled chest pain.
Select...
I do not have chronic illnesses like diabetes, liver or kidney disease, or cancer that could affect the study's outcome.
Select...
I am not taking medications like statins, blood pressure drugs, or antidepressants.
Select...
I don't take more than a daily multivitamin or specific supplements like resveratrol.
Select...
I have heart rhythm problems seen on an EKG or during a fitness test.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~comparing trials separated by one week (supplement vs. placebo)
This trial's timeline: 3 weeks for screening, Varies for treatment, and comparing trials separated by one week (supplement vs. placebo) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Nrf2 activation in response to acute exercise
Secondary study objectives
Glutathione reductase (GR) gene expression in response to acute exercise
HO-1 gene expression in response to acute exercise
NQO1 gene expression in response to acute exercise

Side effects data

From 2013 Phase 2 trial • 20 Patients • NCT01228084
35%
Flatulence
35%
Nausea
20%
Bloating
20%
Diarrhea
20%
Dyspepsia
15%
Gatrointestinal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sulpforaphane

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SFN supplementExperimental Treatment2 Interventions
The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
Group II: PlaceboPlacebo Group2 Interventions
Placebo capsules provided by Cell-Logic.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sulforaphane
2016
Completed Phase 3
~550
Placebo capsules
2015
Completed Phase 3
~4330

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Phytonutrients found in cruciferous vegetables, such as sulforaphane, exert their beneficial effects primarily through their antioxidant and anti-inflammatory properties. These compounds activate cellular pathways that enhance the body's natural defense mechanisms against oxidative stress and inflammation, which are significant contributors to the aging process and age-related diseases. By reducing oxidative damage and inflammatory responses, these phytonutrients can help maintain cellular health, improve vascular function, and potentially lower the risk of chronic diseases such as cardiovascular disease and neurodegenerative disorders. This is particularly important for aging patients as it can improve their overall health and quality of life.
Healthy lifestyle-based approaches for successful vascular aging.Beta carotene: from biochemistry to clinical trials.

Find a Location

Who is running the clinical trial?

Northern Arizona UniversityLead Sponsor
33 Previous Clinical Trials
6,535 Total Patients Enrolled
Villanova UniversityOTHER
7 Previous Clinical Trials
3,191 Total Patients Enrolled

Media Library

Sulforaphane Clinical Trial Eligibility Overview. Trial Name: NCT04848792 — N/A
Age-Related Issues Research Study Groups: SFN supplement, Placebo
~7 spots leftby May 2025